Friday, Nov. 10
|
7 – 8 a.m. |
Breakfast |
Maryland & Cherry Blossom Foyers
|
7 a.m. – 6:30 p.m. |
Registration |
Cherry Blossom Foyer
|
Session 100: National Cancer Institute Update
|
8 – 8:05 a.m. |
Presidential Welcome Lisa H. Butterfield, PhD – University of Pittsburgh
|
Maryland Ballroom |
8:05 – 8:20 a.m. |
National Cancer Institute Update T. Kevin Howcroft, PhD – National Cancer Institute
|
8:20 – 8:35 a.m. |
2016 NCI Immunotherapy Fellowship Update Julius Strauss, MD – National Cancer Institute |
Session 101: Keynote Address
|
8:35 – 8:40 a.m. |
Welcome and Introductions Lisa H. Butterfield, PhD – University of Pittsburgh |
Maryland Ballroom
|
8:40 – 9:20 a.m. |
The CAR T Revolution in Leukemia Stephan Grupp, MD, PhD – University of Pennsylvania |
9:20 – 9:25 a.m. |
Q&A and Closing Remarks Stephan Grupp, MD, PhD – University of Pennsylvania |
Session 102: Science Behind the Therapy: Mechanisms of Efficacy & Toxicity
|
Co-Chairs:
Kevan Herold, MD – Yale University Arlene Sharpe, MD, PhD – Harvard Medical School
|
9:25 – 9:35 a.m. |
Introduction Arlene Sharpe, MD, PhD – Harvard Medical School |
Maryland Ballroom
|
9:35 – 9:55 a.m. |
Clinical Overview of Checkpoint Inhibitors Jeffrey A. Sosman, MD – Northwestern University
|
9:55 – 10:15 a.m. |
Autoimmune Endocrinopathies Kevan Herold, MD – Yale University |
10:15 – 10:30 a.m. |
Break |
Maryland Foyer |
10:30 – 10:50 a.m. |
Colitis Michael Dougan, MD, PhD – Massachusetts General Hospital
|
Maryland Ballroom
|
10:50 – 11:10 a.m. |
Cardiovascular Autoimmunity Andrew Lichtman, MD, PhD – Brigham and Women's Hospital |
11:10 – 11:30 a.m. |
Severe Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analyses of Patient, Protocol and Product Attributes Mark J. Gilbert, MD – Juno Therapeutics, Inc. |
11:30 – 11:45 a.m. |
Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis Jennifer Wu, PhD – Northwestern University |
11:45 a.m. – Noon |
Diversity and Composition of the Gut Microbiome Influences Responses to Anti-PD1-Therapy Through Beneficial Changes in Innate and Adaptive Immunity Vancheswaran Gopalakrishnan, PhD – The University of Texas MD Anderson Cancer Center |
Session 103: Late-Breaking Abstract Session I
|
Noon – 12:15 p.m. |
Interim Safety Analysis of Cancer Immunotherapy Trials Network – 12 (CITN-12): A Phase 1 Study of Pembrolizumab in Patients with HIV and Relapsed, Refractory or Disseminated Malignancies Thomas S. Uldrick, MD – National Cancer Institute |
Maryland Ballroom |
12:15 – 12:30 p.m. |
Nivolumab in Mismatch-Repair Deficient (MMR-d) Cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Arm Z1D Preliminary Results Nilofer Azad, MD – Johns Hopkins University |
12:30 – 2 p.m. |
Lunch & Poster Viewing/Presentations
|
Prince George Exhibition Hall DE |
12:45 – 1:45 p.m. |
Oral Poster Presentations |
Back of Exhibition Hall DE |
Concurrent Session 104: Clinical Trials: New Agents
|
Co-Chairs: |
1:45 – 2 p.m. |
First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors Robert Vonderheide, MD, PhD – Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
|
Maryland Ballroom
|
2 – 2:15 p.m. |
First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies Peter Ellmark, PhD – Alligator Bioscience |
2:15 – 2:30 p.m. |
Monotherapy Dose Escalation Clinical and Translational Data from First-in-Human Study in Advanced Solid Tumors of IPI-549, an Oral, Selective, PI3K-Gamma Inhibitor Targeting Tumor Macrophages David Hong, MD – University of Texas MD Anderson Cancer Center |
2:30 – 2:45 p.m. |
Phase 1 Trial of CA-170, a First-in-Class, Orally Available, Small Molecule Immune Checkpoint Inhibitor (ICI) Dually Targeting PD-L1 and VISTA, in Patients with Advanced Solid Tumors or Lymphomas
Yung Jue Bang, PhD, MD – Seoul National University Hospital
|
2:45 – 3 p.m. |
Phase I trial of IL-15 Superagonist ALT-803 (IL-15N72D:IL-15RαSu/IgG1 Fc complex) in Advanced Solid Tumors: Tolerability and Correlates of Activity Kim Margolin, MD, FACP – City of Hope |
3 – 3:15 p.m. |
Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents James L. Gulley, MD, PhD, FACP – National Cancer Institute
|
3:15 – 3:30 p.m. |
Phase I study of E7046, a Novel PGE2 ReceptorType 4 Inhibitor, in Patients with Advanced Solid Tumors with High Myeloid Infiltrate: Effects on Myeloid - and T-Lymphoid Cell-Mediated Immunosuppression Aurelien Marabelle, MD, PhD – Gustave Roussy Institute |
Concurrent Session 105: Building Personalized Vaccines and Technologies for Hematologic Malignancies and Solid Tumors
|
Co-Chairs:
Matthew M. Gubin, PhD – Washington University of Medicine Catherine J. Wu, MD – Dana-Farber Cancer Institute
|
2 – 2:05 p.m. |
Introduction Matthew M. Gubin, PhD – Washington University School of Medicine |
Cherry Blossom Ballroom |
2:05 – 2:25 p.m. |
Preclinical & Mouse Models Matthew M. Gubin, PhD – Washington University School of Medicine
|
2:25 – 2:45 p.m. |
Tumor Vaccines in AML David E. Avigan, MD – Beth Israel Deaconess Medical Center |
2:45 – 3:05 p.m. |
Improvement in Epitope Discovery Catherine J. Wu, MD – Dana-Farber Cancer Institute |
3:05 – 3:20 p.m. |
Predictive Biomarkers for Response to Anti-CTLA-4 and Anti-PD-1 Immunotherapy in Melanoma Patients Priyanka Subrahmanyam, PhD – Stanford University |
Session 106: High Impact Clinical Trial Results
|
Chair:
Mario Sznol, MD – Yale School of Medicine
|
3:30 – 3:35 p.m. |
Introduction Mario Sznol, MD – Yale School of Medicine |
Maryland Ballroom
|
3:35 – 3:50 p.m. |
Pooled 3-Year Overall Survival Data from Phase II and Phase III Trials of Nivolumab (NIVO) Combined with Ipilimumab (IPI) in Advanced Melanoma F. Stephen Hodi, MD – Dana-Farber Cancer Institute |
3:50 – 4:05 p.m. |
Nivolumab + Ipilimumab (N+I) vs Sunitinib (S) for Treatment-Naïve Advanced or Metastatic Renal Cell Carcinoma (aRCC): Results From CheckMate 214, including Overall Survival by Subgroups Robert J. Motzer, MD – Memorial Sloan Kettering Cancer Center |
4:05 – 4:20 p.m.
|
Immune and Tumor Responses to Human IL-10 (AM0010, Pegilodecakin) Alone or in Combination with Immune Checkpoint Blockade Martin Oft, MD – ARMO BioScience |
4:20 – 4:35 p.m. |
A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors Glen J. Weiss, MD – Western Regional Medical Center Inc. |
4:35 – 4:50 p.m. |
Expert Discussant Samir Khleif, MD – Georgia Cancer Center |
4:50 – 5:05 p.m. |
Break |
Prince George Exhibition Hall DE
|
Concurrent Session 107: Oncolytic Viruses and Intratumoral Therapies
|
Co-Chairs:
Howard L. Kaufman, MD, FACS – Replimune Group, Inc. Samuel Rabkin, PhD – Massachusetts General Hospital
|
5:05 – 5:10 p.m. |
Introduction Howard L. Kaufman, MD, FACS – Replimune Group, Inc. |
Cherry Blossom Ballroom
|
5:10 – 5:30 p.m. |
Oncolytic Viruses in Combination Immunotherapy Approaches Howard L. Kaufman, MD, FACS – Replimune Group, Inc. |
5:30 – 5:50 p.m. |
Oncolytic Herpes Simplex Virus Immunovirotherapy for Glioblastoma Samuel Rabkin, PhD – Massachusetts General Hospital |
5:50 – 6:10 p.m. |
Oncolytic Virus Clinical Data Brian D. Lichty, PhD – McMaster University |
6:10 – 6:25 p.m. |
Preclinical Characterization of a Novel STING Agonist, MK-1454 Saso Cemerski, PhD – Merck Research Laboratories |
6:25 – 6:30 p.m. |
Closing Remarks Samuel Rabkin, PhD – Massachusetts General Hospital
|
Concurrent Session 108: Energizing Immune Cell Metabolism in Cancer
|
Co-Chairs: Nicholas P. Restifo, MD – National Cancer Institute Susan M. Kaech, PhD – Yale University
|
5:05 – 5:25 p.m. |
Anti-Tumor T Cells: You Are What You Eat Susan M. Kaech, PhD – Yale University
|
Maryland Ballroom
|
5:25 – 5:45 p.m. |
Metabolic Control of T Cell Epigenetics Nicholas P. Restifo, MD – National Cancer Institute |
5:45 – 6:05 p.m. |
Metabolic Changes in Tumor Microenvironment Greg M. Delgoffe, PhD – University of Pittsburgh |
6:05 – 6:20 p.m. |
Re-Educating Macrophage through Glutamine Metabolism-Mediated Metabolic and Epigenetic Reprogramming Ping-Chih Ho, PhD – University of Lausanne |
6:20 – 6:35 p.m. |
Lactic Acid as a Mediator of Metabolic Symbiosis Between Regulatory T cells and the Tumor Microenvironment McLane Watson, BS – University of Pittsburgh |
6:30 – 8 p.m. |
Poster Reception Viewing and Presentations
|
Prince George Exhibition Hall DE |
8 – 9 p.m. |
Presidential Reception & Membership Business Meeting |
Cherry Blossom Ballroom
|
Saturday, Nov. 11
|
7 – 8 a.m. |
Breakfast |
Maryland & Cherry Blossom Foyers
|
7 a.m. – 6:30 p.m. |
Registration |
Cherry Blossom Foyer
|
8 – 8:05 a.m. |
Organizer Welcome Charles G. Drake, MD, PhD – Columbia University Medical Center |
Maryland Ballroom
|
Session 200: Update Session - Cancer Immunotherapy Trials Network (CITN) Update
|
8:05 – 8:35 a.m. |
Cancer Immunotherapy Trials Network (CITN) Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center |
Maryland Ballroom
|
Session 201: Richard V. Smalley, MD Memorial Lectureship
|
8:35 – 8:40 a.m. |
Introduction Lisa H. Butterfield, PhD – University of Pittsburgh |
Maryland Ballroom
|
8:40 – 9:20 a.m. |
Activation of Innate and Adaptive Immunity as an In Situ Cancer Vaccine Paul M. Sondel, MD, PhD – University of Wisconsin, Madison |
9:20 – 9:25 a.m. |
Q&A and Closing Remarks Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
|
Session 202: Mechanisms of Acquired Resistance to Immunotherapies
|
Co-Chairs:
Katerina Politi, PhD – Yale School of Medicine Antoni Ribas, MD, PhD – University of California, Los Angeles
|
9:25 – 9:30 a.m. |
Introduction Katerina Politi, PhD – Yale School of Medicine |
Maryland Ballroom |
9:30 – 9:55 a.m. |
Acquired Resistance Checkpoint Inhibitors in Lung Cancer Katerina Politi, PhD – Yale School of Medicine
|
9:55 – 10:20 a.m. |
Acquired Resistance to PD-1 Blockade in Melanoma Antoni Ribas, MD, PhD – University of California, Los Angeles
|
10:20 – 10:45 a.m. |
Break |
Prince George Exhibition Hall DE |
10:45 – 11:10 a.m. |
Acquired Resistance in Melanoma Annette Paschen, MD – University Hospital Essen |
Maryland Ballroom
|
11:10 – 11:25 a.m. |
Single Cell RNA Sequencing Reveals Mechanisms of Merkel Cell Carcinoma Escape from Intense Pressure of T Cell Immunotherapy Kelly Paulson, MD, PhD – Fred Hutchinson Cancer Research Center |
11:25 – 11:40 a.m. |
A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance Jason Williams, BS – University of Chicago |
11:40 – 11:55 a.m. |
Functional Correlation of Increased Tumor Intrinsic Glycolytic Activity with Resistance to Adoptive T Cell Therapy Weiyi Peng, MD, PhD – The University of Texas MD Anderson Cancer Center |
11:55 a.m. – Noon |
Closing Remarks Antoni Ribas, MD, PhD – University of California, Los Angeles |
Session 203: Late Breaking Abstract Session II
|
12 – 12:15 p.m. |
Preliminary antitumor and immunomodulatory activity of BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, in combination with nivolumab in patients with advanced cancers Jason J. Luke, MD – University of Chicago Medical Center |
Maryland Ballroom
|
12:15 – 12:30 p.m. |
The transcription factor Myb enhances CD8+ T cell stemness and polyfunctionality to promote curative antitumor immunity Sanjivan Gautam, PhD – National Cancer Institute |
12:30 – 2 p.m. |
Lunch & Poster Viewing/Presentations |
Prince George Exhibition Hall DE
|
12:45 – 1:45 p.m. |
Oral Poster Presentations |
Back of Prince George Exhibition Hall DE
|
Concurrent Session 204: Presidential Session
|
2 – 2:05 p.m. |
Introduction Lisa H. Butterfield, PhD – University of Pittsburgh |
Maryland Ballroom C |
2:05 – 2:20 p.m. |
Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors Vinod Balachandran, MD – Memorial Sloan Kettering Cancer Center |
2:20 – 2:35 p.m. |
Neoadjuvant Nivolumab Versus Combination Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Patients with Resectable Stage III and Oligometastatic Stage IV Melanoma: Preliminary Findings Sangeetha M. Reddy, MD, MSc – The University of Texas MD Anderson Cancer Center |
2:35 – 2:45 p.m. |
Expert Discussant Charles Drake, MD, PhD – Columbia University Medical Center
|
2:45 – 3 p.m. |
Cross-Dressed Dendritic Cells Drive Anti-Tumor Immunity Brendan MacNabb, BS – The University of Chicago |
3 – 3:15 p.m. |
Metabolic Adaptations Establish Immunotherapy Resistance in Melanoma Ashvin R. Jaiswal, DPharm, MS, PhD – UT MD Anderson Cancer Center |
3:15 – 3:25 p.m. |
Expert Discussant Susan M. Kaech, PhD – Yale University |
Concurrent Session 205: Tumor Immunology 101 (Physician/Nurse/Pharmacy Track)
|
Co-Chairs:
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
|
2 – 2:05 p.m. |
Introduction Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute |
Cherry Blossom Ballroom
|
2:05 – 2:30 p.m. |
Immunology 101 for the Non-Immunologist Yvonne Saenger, MD – Columbia University Medical Center |
2:30 – 2:55 p.m. |
Basic Principles of Tumor Immunotherapy Michael K. Wong, MD, PhD, FRCPC – MD Anderson Cancer Center |
2:55 – 3:20 p.m. |
Drug Classification & MOAs Lisa M. Cordes, PharmD, BCACP, BCOP – National Cancer Institute |
3:20 – 3:25 p.m. |
Closing Remarks Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital |
3:25 – 3:40 p.m. |
Break |
Cherry Blossom Foyer |
Concurrent Session 206: Economics of Immunotherapies and Immunotherapy Combinations
|
Co-Chairs:
Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center Bruce Levine, PhD – Abramson Cancer Center
|
3:25 – 3:27 p.m. |
Introduction Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
|
Maryland Ballroom C
|
3:27 – 3:42 p.m. |
Report on Economics of Checkpoint Inhibitors in Melanoma Ahmad Tarhini, MD, PhD – University of Pittsburgh Cancer Institute |
3:42 – 3:57 p.m. |
Report on Economics of Adoptive Cell Therapy Richard Maziarz, MD – Oregon Health & Science University |
3:57 – 4 p.m. |
Q&A and Closing Remarks |
4 – 4:15 p.m. |
Plenary Session Break |
Maryland Foyer |
Concurrent Session 207: Clinical Trials: Novel Combinations
|
Co-Chairs: |
3:30 – 3:45 p.m. |
A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase Inhibitor, Combined with Nivolumab in Patients with Advanced Melanoma (MEL), Renal Cell Carcinoma (RCC), or Non-Small Cell Lung Cancer (NSCLC) Funda Meric-Bernstam, MD – The University of Texas MD Anderson Cancer Center |
Maryland Ballroom A |
3:45 – 4 p.m. |
ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combination with Pembrolizumab (PEMBRO) in Patients with Non-Small Cell Lung Cancer (NSCLC) Leena Gandhi, MD, PhD – NYU Langone Medical Center |
4 – 4:15 p.m. |
OX40 T-cell Costimulatory Agonist BMS-986178 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results Anthony J. Olszanski, MD – Fox Chase Cancer Center |
4:15 – 4:30 p.m. |
Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab Jose Saro, MD – Roche Innovation Center Zurich |
4:30 - 4:45 p.m. |
First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors Zev Wainberg, MD – UCLA School of Medicine |
4:45 – 5 p.m. |
TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Infiltrating T Cell Expansion in Distant Lesions in a Phase 1/2 Study of Intratumoral IMO-2125+ipilimumab in Anti-PD1 Refractory Melanoma Patients Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center |
5 – 5:15 p.m. |
Pivot-02: Preliminary Safety, Efficacy and Biomarker Results from the Phase 1/2 Study of CD-122-Biased Agonist NKTR-214 Plus Nivolumab in Patients with Locally Advanced/Metastatic Solid Tumors Adi Diab, MD – The University of Texas MD Anderson Cancer Center |
5:15 – 5:30 p.m. |
DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC) Douglas McNeel, MD, PhD – University of Wisconsin |
5:30 – 5:45 p.m. |
A Dendritic Cell Targeting NY-ESO-1 Vaccine Significantly Augments Early and Durable Immune Responses in Melanoma Patients Pretreated with Human Flt-3 Ligand Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
|
5:45 – 6 p.m. |
Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation Jason Luke, MD – University of Chicago Medical Center
|
Concurrent Session 208: Clinical Management (Physician/Nurse/Pharmacy Track)
|
Co-Chairs:
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
|
3:40 – 3:45 p.m. |
Introduction Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute |
Cherry Blossom Ballroom
|
3:45 – 4:15 p.m. |
General Concepts of Toxicity Management Michael Postow, MD – Memorial Sloan Kettering Cancer Center |
4:15 – 4:35 p.m. |
Pharmacological Management of irAEs Nathan Dahl, PharmD, R.Ph, BCOP – Clovis Oncology
|
4:35 – 5 p.m. |
Panel Discussion: Management of Complex Adverse Events Moderator: Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Panel: Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital Nathan Dahl, PharmD – Mayo Clinic Michael Postow, MD – Memorial Sloan Kettering Cancer Center |
5 – 5:15 p.m. |
Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool Krista Marcello, BA – Clinical Care Options, LLC |
5:15 – 5:30 p.m. |
Audience Question & Answer Moderator: Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
|
Concurrent Session 209: Emerging Models & Imaging
|
Co-Chairs:
Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health
|
4:15 – 4:20 p.m. |
Introduction Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health
|
Maryland Ballroom C
|
4:20 – 4:40 p.m. |
Imaging Immunity - Developing a Spatiotemporal Understanding of Host Defense and Tumor Immunity Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health |
4:40 – 5 p.m. |
Molecular Imaging of Checkpoint Blockade Sridhar Nimmagadda, PhD – Johns Hopkins University |
5 – 5:20 p.m. |
Multiplex Three-Dimensional Optical Mapping of Tumor Immune Microenvironment Steve Seung-Young Lee, PhD – University of Chicago |
5:20 – 5:35 p.m. |
Combining Immunophenomics with a Gene Expression Panel for Improved Prostate Cancer Recurrence Prediction Nathalie Harder, PhD – Definiens AG |
5:35 – 5:40 p.m. |
Closing Remarks
|
Award Ceremony
|
6:00 – 6:30 p.m. |
Award Ceremony Lisa H. Butterfield, PhD – University of Pittsburgh |
Maryland Ballroom C
|
6:30 – 8 p.m. |
Evening Poster Reception & Viewing |
Prince George Exhibition Hall DE
|
8:30 – 11:30 p.m. |
The CheckPoints Party |
Maryland Ballroom
|
Sunday, Nov. 12
|
7 – 8 a.m. |
Breakfast |
Cherry Blossom Foyer
|
7 – 10 a.m. |
Registration |
Cherry Blossom Foyer
|
8 – 8:05 a.m. |
Organizer Welcome Marcela V. Maus, MD, PhD – Massachusetts General Hospital
|
Cherry Blossom Ballroom
|
Session 300: Genetically Modified Cell Therapy
|
SITC is pleased to offer a live streaming webcast of Session 300: Genetically Modified Cell Therapy. Click here for more information and to register for the webcast.
Organized in collaboration with the American Society for Blood and Marrow Transplantation (ASBMT)
|
Co-Chairs:
Marcela V. Maus, MD, PhD – Massachusetts General Hospital Carl H. June, MD – University of Pennsylvania Helen E. Heslop, MD – Baylor College of Medicine
|
8:05 – 8:30 a.m. |
CAR T Cells Smarter Targeting and Smarter Targets Martin Pule, PhD – University College London |
Cherry Blossom Ballroom
|
8:30 – 8:55 a.m. |
Updates in CAR T cells Crystal L. Mackall, MD – Stanford University |
8:55 – 9:20 a.m. |
Genetically Modified T Cells for Solid Tumors Stephen Gottschalk, MD – St. Jude Children's Research Hospital |
9:20 – 9:45 a.m. |
Late-Breaking: CD19 CAR Enter the Mainstream Jennifer Brogdon – Novartis Institute of Biomedical Research |
9:45 – 10 a.m. |
Transcriptional Approach to Understanding the Role of Tonic Signaling and Co-Stimulation in CAR T cells Angela Boroughs, BS – Massachusetts General Hospital, Harvard University |
10 – 10:15 a.m. |
Gamma Secretase Inhibition Increases Recognition of Multiple Myeloma by BCMA-Specific Chimeric Antigen Receptor Modified T Cells Margot Pont, PhD – Fred Hutchinson Cancer Research Center |
|
SITC is pleased to offer a live streaming webcast of Session 301: Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy? Click here for more information and to register for the webcast.
Organized in collaboration with Stand Up To Cancer
|
Co-Chairs: Howard Kaufman, MD, FACS – Replimune Group, Inc. Herbert Levine, PhD – Rice University
|
10:30 – 10:35 a.m. |
Welcome and Introductions Howard Kaufman, MD, FACS – Replimune Group, Inc.
|
Cherry Blossom Ballroom
|
10:35 – 10:55 a.m. |
Overview of the Immunotherapy Field Francesco M. Marincola, MD – AbbVie Inc. |
10:55 – 11:15 a.m. |
Integrating Multiple Dimensions of Genomic Data as Immunotherapy Predictive Biomarkers Thomas F. Gajewski, MD, PhD – University of Chicago |
11:15 – 11:35 a.m. |
Challenges in Clinical Development Michael Postow, MD – Memorial Sloan Kettering Cancer Center
|
11:35 – 11:55 a.m. |
Systems of Biology Modeling of the Immune System Doron Levy, PhD – University of Maryland |
11:55 – 12:15 p.m. |
T Cell Repertoire Curtis Callan, PhD – Princeton University
|
12:15 – 12:35 p.m. |
Modeling the Fitness Costs of Neoantigens Benjamin Greenbaum, PhD – Tisch Cancer Institute
|
12:35 – 1 p.m. |
Panel Discussion Moderators: Howard Kaufman, MD, FACS – Replimune Group, Inc. Herbert Levine, PhD – Rice University
|